NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $0.77 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.04%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Oncolytics Biotech Stock (NASDAQ:ONCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncolytics Biotech alerts:Sign Up Key Stats Today's Range$0.76▼$0.7850-Day Range$0.75▼$0.9352-Week Range$0.73▼$1.51Volume491,478 shsAverage Volume886,085 shsMarket Capitalization$98.18 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational form of reovirus designed to selectively target certain cancer cells and stimulate an immune response against tumors. Oncolytics is evaluating pelareorep in combination with other cancer treatments, including immune checkpoint inhibitors and chemotherapy. Its research has focused primarily on breast cancer, pancreatic cancer and other solid tumors, with development programs conducted through collaborations and clinical studies in North America and other regions. Founded in 1998 and headquartered in Calgary, Alberta, Oncolytics Biotech operates as a development-stage biotechnology company. Pelareorep has not been approved for commercial sale, and the company’s programs remain subject to clinical, regulatory and other development requirements.AI Generated. May Contain Errors. Read More Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreONCY MarketRank™: Oncolytics Biotech scored higher than 39% of companies evaluated by MarketBeat, and ranked 635th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingOncolytics Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialOncolytics Biotech has a consensus price target of $5.00, representing about 549.4% upside from its current price of $0.77.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncolytics Biotech are expected to grow in the coming year, from ($0.29) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oncolytics Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.13% of the float of Oncolytics Biotech has been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 13.48, which indicates bearish sentiment.Change versus previous monthShort interest in Oncolytics Biotech has recently decreased by 7.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest10 people have searched for ONCY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by Institutions6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCY Stock News HeadlinesOncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal CancerSeptember 10, 2026 | finanznachrichten.deOncolytics Biotech Reports Preclinical Pelareorep Activity Maintained with RAS InhibitionSeptember 10, 2026 | quiverquant.comQMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 20 at 1:00 AM | Paradigm Press (Ad)Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal CancerSeptember 10, 2026 | globenewswire.comOncolytics Biotech gains FDA alignment on REO 033 trialAugust 20, 2026 | theglobeandmail.comOncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal CancerAugust 18, 2026 | globenewswire.comOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal CancerJuly 20, 2026 | globenewswire.comONCY: Seeking Registration Pathway for Part B of REO 033 TrialJuly 16, 2026 | finance.yahoo.comSee More Headlines ONCY Stock Analysis - Frequently Asked Questions How have ONCY shares performed this year? Oncolytics Biotech's stock was trading at $0.8740 at the beginning of 2026. Since then, ONCY stock has decreased by 11.9% and is now trading at $0.77. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. Who are Oncolytics Biotech's major shareholders? Oncolytics Biotech's top institutional shareholders include Connective Capital Management LLC (0.15%), Susquehanna International Group LLP (0.11%) and Vantage Point Financial LLC (0.02%). Insiders that own company stock include Bernd R Seizinger, Wayne Pisano, Kirk Look, Thomas Charles Heineman, Allison Hagerman, Jared Kelly, Deborah Margaret Brown, Patricia S Andrews, Andrew Aromando and James T Parsons. View institutional ownership trends. How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), Qualcomm (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/12/2026Today9/20/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ONCY's financial health is in the Yellow zone, according to TradeSmith. ONCY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ONCY CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees29Year Founded1998Price Target and Rating Average Price Target for Oncolytics Biotech$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+549.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-2,185.97% Return on Assets-442.99% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-19.25Miscellaneous Outstanding Shares127,510,000Free Float127,383,000Market Cap$98.18 million OptionableNot Optionable Beta1.15 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ONCY) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
